Santa Rosa medical technology maker TriVascular Inc. has raised $4 million in new venture capital as it readies a new medical device for the U.S. market.

TriVascular is conducting clinical trials on the Ovation Abdominal Stent Graft, a system for repairing abdominal aortic aneurysms.

The Ovation device has already been approved for sale in Europe, where it was launched in January 2011.

TriVascular won regulatory approval last November for limited use of Ovation in the United States. It has a similar clearance in Canada.

TriVascular disclosed the latest venture deal in a filing earlier this month with securities regulators.

The company reported a $7.2 million investment in February. TriVascular has raised more than $100 million in past rounds of venture funding.

Its investors include Delphi Venture Partners, Kearny Venture Partners, MPM Capital, New Enterprise Associates and Pinnacle Ventures.